EUVIMEDEUVIMED entdecken
Leserbrief

Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?

Y Xue, J Yan

Clinical Oncology · 2026-07 · 55 · 104170

DOI: 10.1016/j.clon.2026.104170 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Oncology, 2026-07. Verfasst von Y Xue und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China.
  • Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China. Electronic address: 13834534594@163.com.

Zitieren

APA

Xue, Y., & Yan, J. (2026). Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?. Clinical Oncology, 55, 104170. https://doi.org/10.1016/j.clon.2026.104170

Vancouver

Xue Y, Yan J. Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?. Clinical Oncology. 2026;55:104170. doi:10.1016/j.clon.2026.104170

BibTeX
@article{Xue2026,
  author = {Xue, Y and Yan, J},
  title = {Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {55},
  pages = {104170},
  doi = {10.1016/j.clon.2026.104170}
}
Kostenlos starten →